Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Sonnet Biotherapeutics Holdings Inc SONN

Consumer Cyclical Biotechnology
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SONN)

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

Accesswire March 19, 2024

Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Accesswire March 11, 2024

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

Accesswire February 29, 2024

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Accesswire February 14, 2024

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

Accesswire December 21, 2023

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

Accesswire December 14, 2023

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

Accesswire October 31, 2023

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering

Accesswire October 25, 2023

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Accesswire October 17, 2023
View More News ››

Opinion & Analysis (NDAQ:SONN)

Natural gas shortage may drive (T.HNU) higher

Stockhouse Editorial January 22, 2014
View More Opinion ››

Bullboard Posts (NDAQ:SONN)

SONN..... what a dump !

I might have left a fair bit on the table by selling a little too early.....but I've got money in my pocket going ging-a ling It'...
Iseneschal - October 31, 2022

SONN .... Just here to inform you ; )

You better do some research.....just sayin....there's a reason for all this volume ... You might wany to put this puzzle together...
Iseneschal - October 31, 2022

SONN ....Just to let u know .....

$2.73 is break even for the Reverse Split holders way back in Sept 16th of 2022  Cheers ! oh .... I forgot ....... Cha F'king...
Iseneschal - October 31, 2022

SONN .... Geez..... my calls really suck eh?

Now over $2.55..... LMFAO
Iseneschal - October 31, 2022

RE:RE:SONN ..... Sorry Folks.... Can't please everyone ; )

You're turning this into a "pissing match".......LMFAO WEED.....LoL Canopy Growth loses $2.08-billion in fiscal Q1...
Iseneschal - October 31, 2022

RE:SONN ..... Sorry Folks.... Can't please everyone ; )

WEED  called it bro...lol
Chefboy69 - October 31, 2022
View more Bullboard ››

Etruscus Resources Corp.

Etruscus Resources Corp.

Etruscus Resources is a precious and critical metals exploration company focused on the development of two properties that ...
View More »